Fundamental Analysis of BIONOMICS LTD-ADR(NASDAQ:BNOX) stock

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to BNOX. BNOX was compared to 566 industry peers in the Biotechnology industry. BNOX has a bad profitability rating. Also its financial health evaluation is rather negative. BNOX does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year BNOX has reported negative net income.

BNOX had a negative operating cash flow in the past year.

BNOX had negative earnings in each of the past 5 years.

BNOX had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

With a Return On Assets value of -74.06%, BNOX is not doing good in the industry: 69.70% of the companies in the same industry are doing better.

BNOX has a Return On Equity of -96.08%. This is comparable to the rest of the industry: BNOX outperforms 45.45% of its industry peers.

		Industry Rank	Sector Rank
ROA	-74.06%
ROE	-96.08%
ROIC	N/A

ROA(3y)-41.13%

ROA(5y)-32.67%

ROE(3y)-50.86%

ROE(5y)-54.3%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BNOX so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

BNOX does not have a ROIC to compare to the WACC, probably because it is not profitable.

BNOX has more shares outstanding than it did 1 year ago.

The number of shares outstanding for BNOX has been increased compared to 5 years ago.

The debt/assets ratio for BNOX is higher compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of -8.19, we must say that BNOX is in the distress zone and has some risk of bankruptcy.

With a Altman-Z score value of -8.19, BNOX is not doing good in the industry: 73.08% of the companies in the same industry are doing better.

A Debt/Equity ratio of 0.01 indicates that BNOX is not too dependend on debt financing.

BNOX has a Debt to Equity ratio (0.01) which is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0.01
Debt/FCF	N/A
Altman-Z	-8.19

ROIC/WACCN/A

WACC10.37%

2.3 Liquidity

A Current Ratio of 4.87 indicates that BNOX has no problem at all paying its short term obligations.

BNOX has a Current ratio (4.87) which is comparable to the rest of the industry.

A Quick Ratio of 4.87 indicates that BNOX has no problem at all paying its short term obligations.

The Quick ratio of BNOX (4.87) is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Current Ratio	4.87
Quick Ratio	4.87

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for BNOX have decreased strongly by -12.51% in the last year.

BNOX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -91.64%.

Measured over the past years, BNOX shows a very negative growth in Revenue. The Revenue has been decreasing by -64.58% on average per year.

EPS 1Y (TTM)-12.51%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-53.34%

Revenue 1Y (TTM)-91.64%

Revenue growth 3Y-22.11%

Revenue growth 5Y-64.58%

Sales Q2Q%-91.64%

3.2 Future

BNOX is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -16.76% yearly.

The Revenue is expected to grow by 118.41% on average over the next years. This is a very strong growth

EPS Next Y-6.33%

EPS Next 2Y-10.34%

EPS Next 3Y-16.76%

EPS Next 5YN/A

Revenue Next Year-70.47%

Revenue Next 2Y-32.84%

Revenue Next 3Y118.41%

Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BNOX. In the last year negative earnings were reported.

Also next year BNOX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

BNOX's earnings are expected to decrease with -16.76% in the coming years. This may justify a cheaper valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-10.34%

EPS Next 3Y-16.76%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

BNOX does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

BIONOMICS LTD-ADR

NASDAQ:BNOX (10/28/2024, 8:04:54 PM)

After market: 0.1939 0 (-0.21%)

0.1943

-0.05 (-21.27%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap2.57M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-74.06%
ROE	-96.08%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0.01
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	4.87
Quick Ratio	4.87
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)-12.51%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y-6.33%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-91.64%

Revenue growth 3Y-22.11%

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

BIONOMICS LTD-ADR (BNOX)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens